Santen Pharmaceutical Co., Ltd. (TYO:4536)

Market Cap	538.64B +2.6%
Revenue (ttm)	291.84B -0.7%
Net Income	38.68B +22.8%
EPS	119.40 +30.6%
Shares Out	321.19M
PE Ratio	14.04
Forward PE	13.10
Dividend	42.00 (2.50%)
Ex-Dividend Date	Sep 29, 2026

Volume	944,000
Open	1,689.50
Previous Close	1,683.50
Day's Range	1,672.50 - 1,690.50
52-Week Range	1,458.00 - 2,254.00
Beta	0.25
Analysts	Buy
Price Target	2,377.78 (+41.79%)
Earnings Date	Nov 5, 2026

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments. It products include Taflupro/Timolol maleate, a combination drug of a prostaglandin Fa derivative and a beta-blocker for the treatment of glaucoma and ocular hypertension area; omidenepagisopropyl, an EP2 receptor agonist that ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1890
• Employees: 3,968
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4536

Financial Performance

In fiscal year 2026, Santen Pharmaceutical's revenue was 291.62 billion, a decrease of -2.79% compared to the previous year's 300.00 billion. Earnings were 37.36 billion, an increase of 3.07%.

Analyst Summary

According to 9 analysts, the average rating for 4536 stock is "Buy." The 12-month stock price target is ¥2,378, which is an increase of 41.79% from the latest price.

Price Target

¥2,378

(41.79% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 7, 2026

Data Sources Report a data error